Sign in Subscribe

chemo

A collection of 72 issues

Oxaliplatin-Induced Neuropathy Tracked in Survivors Up to 2 Years Post-Treatment

Skip to content The CRC Digest ♥ LIVING WITH CRC Oxaliplatin-Induced Neuropathy Tracked in Survivors Up to 2 Years Post-Treatment A prospective study of 106 stage II-III colon cancer patients treated with adjuvant CAPOX examined associations between oxaliplatin dosing and chemotherapy-induced peripheral neuropathy, with assessments continuing up to 24 months after

Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer

Skip to content The CRC Digest ◇ RESEARCH Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer Adding immune checkpoint blockade to chemoradiotherapy has been associated with pathological complete response rates of 30% or more in pMMR rectal cancer trials, higher than expected with chemoradiotherapy alone, though

Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response

Skip to content The CRC Digest Prospective study examines MSI and CD8+ TILs in neoadjuvant chemotherapy response A prospective observational study investigated whether microsatellite instability, CD8+ tumor infiltrating lymphocytes expression, and chemotherapy response are related in colorectal cancer patients receiving neoadjuvant treatment. (Cancer Manag Res) This content is informational only

Phase II trial examines quality of life with panitumumab-based intensified regimen

Skip to content The CRC Digest Phase II trial examines quality of life with panitumumab-based intensified regimen The VOLFI trial analyzed health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with mFOLFOXIRI plus panitumumab versus FOLFOXIRI, noting that anti-EGFR antibodies like panitumumab are associated with a

Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases

Skip to content The CRC Digest Pooled Analysis Examines Prognostic Value of KRAS Mutations and Liver Metastases A pooled analysis of third-line placebo-controlled trials from the ARCAD CRC Database evaluated the prognostic impact of liver metastases and KRAS mutations in metastatic colorectal cancer patients. (Clinical Colorectal Cancer) This content is

Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease

Skip to content The CRC Digest ♥ LIVING WITH CRC Quality of life analysis from phase II VOLFI trial compares chemotherapy regimens in RAS wild-type metastatic disease A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial examined quality of life in patients with RAS wild-type metastatic colorectal cancer

Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab

Skip to content The CRC Digest ▸ TREATMENT Real-world study of 549 Spanish patients evaluates trifluridine/tipiracil plus bevacizumab A multicenter study across 19 Spanish hospitals evaluated real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer after at least two prior treatment regimens. (ESMO Gastrointestinal

PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy

Skip to content The CRC Digest ▸ TREATMENT PD-L1 blockade shows activity in MSS rectal cancer when combined with radiation and chemotherapy The PRECAM-R trial demonstrated that short-course radiotherapy may create an immune-priming window in microsatellite-stable tumors, allowing PD-L1 blockade to achieve a 44.8% pathologic complete response rate. (The ASCO

Envafolimab plus chemoradiation improves pathologic complete response in MSS rectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Envafolimab plus chemoradiation improves pathologic complete response in MSS rectal cancer An interim analysis of the phase III PRECAM-R trial found that adding subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX improved pathologic complete response to 44.8% in patients with

Network analysis reveals symptom cluster stability during adjuvant chemotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Network analysis reveals symptom cluster stability during adjuvant chemotherapy A prospective longitudinal study used network temperature to characterize temporal changes in symptom clusters among postoperative colorectal cancer patients receiving adjuvant chemotherapy, finding that symptom burden compromises quality of life. (Supportive Care